Login Register Cart 0
Generic placeholder image

Current Genomics

Editor-in-Chief

ISSN (Print): 1389-2029
ISSN (Online): 1875-5488

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Trop-2 as an Actionable Biomarker in Breast Cancer

Author(s): Giulia Cursano, Emanuele Frigo, Elham Sajjadi, Mariia Ivanova, Konstantinos Venetis, Elena Guerini-Rocco, Carmen Criscitiello, Giuseppe Curigliano and Nicola Fusco*

Volume 24, Issue 3, 2023

Published on: 01 August, 2023

Page: [129 - 131] Pages: 3

DOI: 10.2174/1389202924666230726112233

Price: $65

Next »
[1]
Goldenberg, D.M.; Stein, R.; Sharkey, R.M. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget, 2018, 9(48), 28989-29006.
[http://dx.doi.org/10.18632/oncotarget.25615] [PMID: 29989029]
[2]
Vranic, S.; Palazzo, J.; Sanati, S.; Florento, E.; Contreras, E.; Xiu, J.; Swensen, J.; Gatalica, Z. Potential novel therapy targets in neuroendocrine carcinomas of the breast. Clin. Breast Cancer, 2019, 19(2), 131-136.
[http://dx.doi.org/10.1016/j.clbc.2018.09.001] [PMID: 30268765]
[3]
Zeng, P.; Chen, M.B.; Zhou, L.N.; Tang, M.; Liu, C.Y.; Lu, P.H. Impact of TROP2 expression on prognosis in solid tumors: A systematic review and meta-analysis. Sci. Rep., 2016, 6(1), 33658.
[http://dx.doi.org/10.1038/srep33658] [PMID: 27645103]
[4]
Vidula, N.; Yau, C.; Rugo, H.S. Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics. J. Clin. Oncol., 2023, 35(S15), 1075-1075.
[http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.1075]
[5]
Jeon, Y.; Jo, U.; Hong, J.; Gong, G.; Lee, H.J. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. BMC Cancer, 2022, 22(1), 1014.
[http://dx.doi.org/10.1186/s12885-022-10076-7] [PMID: 36153494]
[6]
Lombardi, P.; Filetti, M.; Falcone, R.; Altamura, V.; Paroni Sterbini, F.; Bria, E.; Fabi, A.; Giannarelli, D.; Scambia, G.; Daniele, G. Overview of trop-2 in cancer: From pre-clinical studies to future directions in clinical settings. Cancers, 2023, 15(6), 1744.
[http://dx.doi.org/10.3390/cancers15061744] [PMID: 36980630]
[7]
Carey, L.A.; Loirat, D.; Punie, K.; Bardia, A.; Diéras, V.; Dalenc, F.; Diamond, J.R.; Fontaine, C.; Wang, G.; Rugo, H.S.; Hurvitz, S.A.; Kalinsky, K.; O’Shaughnessy, J.; Loibl, S.; Gianni, L.; Piccart, M.; Zhu, Y.; Delaney, R.; Phan, S.; Cortés, J. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis. NPJ Breast Cancer, 2022, 8(1), 72.
[http://dx.doi.org/10.1038/s41523-022-00439-5] [PMID: 35680967]
[8]
Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Brufsky, A.; Sardesai, S.D.; Kalinsky, K.; Zelnak, A.B.; Weaver, R.; Traina, T.; Dalenc, F.; Aftimos, P.; Lynce, F.; Diab, S.; Cortés, J.; O’Shaughnessy, J.; Diéras, V.; Ferrario, C.; Schmid, P.; Carey, L.A.; Gianni, L.; Piccart, M.J.; Loibl, S.; Goldenberg, D.M.; Hong, Q.; Olivo, M.S.; Itri, L.M.; Rugo, H.S. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med., 2021, 384(16), 1529-1541.
[http://dx.doi.org/10.1056/NEJMoa2028485] [PMID: 33882206]
[9]
Spring, L.; Tolaney, S.M.; Desai, N.V.; Fell, G.; Trippa, L.; Comander, A.H.; Mulvey, T.M.; McLaughlin, S.; Ryan, P.; Rosenstock, A.S. Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial. J. Clin. Oncol., 2022, 40(S16), 512-512.
[http://dx.doi.org/10.1200/JCO.2022.40.16_suppl.512]
[10]
Tagawa, S.T.; Balar, A.V.; Petrylak, D.P.; Kalebasty, A.R.; Loriot, Y.; Fléchon, A.; Jain, R.K.; Agarwal, N.; Bupathi, M.; Barthelemy, P.; Beuzeboc, P.; Palmbos, P.; Kyriakopoulos, C.E.; Pouessel, D.; Sternberg, C.N.; Hong, Q.; Goswami, T.; Itri, L.M.; Grivas, P. TROPHY-U-01: A Phase ii open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J. Clin. Oncol., 2021, 39(22), 2474-2485.
[http://dx.doi.org/10.1200/JCO.20.03489] [PMID: 33929895]
[11]
Krop, I.; Juric, D.; Shimizu, T.; Tolcher, A.; Spira, A.; Mukohara, T.; Lisberg, A.E.; Kogawa, T.; Papadopoulos, K.P.; Hamilton, E. Abstract GS1-05: Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study. Cancer Res., 2022, 82(4)
[http://dx.doi.org/10.1158/1538-7445.SABCS21-GS1-05]
[12]
Guerra, E.; Trerotola, M.; Aloisi, A.L.; Tripaldi, R.; Vacca, G.; La Sorda, R.; Lattanzio, R.; Piantelli, M.; Alberti, S. The Trop-2 signalling network in cancer growth. Oncogene, 2013, 32(12), 1594-1600.
[http://dx.doi.org/10.1038/onc.2012.151] [PMID: 22562244]
[13]
Bychkov, A.; Sampatanukul, P.; Shuangshoti, S.; Keelawat, S. TROP-2 immunohistochemistry: A highly accurate method in the differential diagnosis of papillary thyroid carcinoma. Pathology, 2016, 48(5), 425-433.
[http://dx.doi.org/10.1016/j.pathol.2016.04.002] [PMID: 27311870]
[14]
Turan, Z.; Erkılıç, S. TROP2: A potential marker in diagnosis of thyroid neoplasms. Ir. J. Med. Sci., 2023, 192(1), 99-103.
[http://dx.doi.org/10.1007/s11845-022-02976-1] [PMID: 35355197]
[15]
Bardia, A.; Tolaney, S.M.; Punie, K.; Loirat, D.; Oliveira, M.; Kalinsky, K.; Zelnak, A.; Aftimos, P.; Dalenc, F.; Sardesai, S.; Hamilton, E.; Sharma, P.; Recalde, S.; Gil, E.C.; Traina, T.; O’Shaughnessy, J.; Cortes, J.; Tsai, M.; Vahdat, L.; Diéras, V.; Carey, L.A.; Rugo, H.S.; Goldenberg, D.M.; Hong, Q.; Olivo, M.; Itri, L.M.; Hurvitz, S.A. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Ann. Oncol., 2021, 32(9), 1148-1156.
[http://dx.doi.org/10.1016/j.annonc.2021.06.002] [PMID: 34116144]
[16]
Starodub, A.N.; Ocean, A.J.; Shah, M.A.; Guarino, M.J.; Picozzi, V.J., Jr; Vahdat, L.T.; Thomas, S.S.; Govindan, S.V.; Maliakal, P.P.; Wegener, W.A.; Hamburger, S.A.; Sharkey, R.M.; Goldenberg, D.M. First-in-human trial of a novel anti-trop-2 antibody-sn-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin. Cancer Res., 2015, 21(17), 3870-3878.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-3321] [PMID: 25944802]
[17]
Vranic, S.; Gatalica, Z. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers. Bosn. J. Basic Med. Sci., 2021, 22(1), 14-21.
[http://dx.doi.org/10.17305/bjbms.2021.6100] [PMID: 34181512]
[18]
King, G.T.; Eaton, K.D.; Beagle, B.R.; Zopf, C.J.; Wong, G.Y.; Krupka, H.I.; Hua, S.Y.; Messersmith, W.A.; El-Khoueiry, A.B. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest. New Drugs, 2018, 36(5), 836-847.
[http://dx.doi.org/10.1007/s10637-018-0560-6] [PMID: 29333575]
[19]
Aslan, M.; Hsu, E.C.; Garcia-Marques, F.J.; Bermudez, A.; Liu, S.; Shen, M.; West, M.; Zhang, C.A.; Rice, M.A.; Brooks, J.D.; West, R.; Pitteri, S.J.; Győrffy, B.; Stoyanova, T. Oncogene-mediated metabolic gene signature predicts breast cancer outcome. NPJ Breast Cancer, 2021, 7(1), 141.
[http://dx.doi.org/10.1038/s41523-021-00341-6] [PMID: 34711841]
[20]
Izci, H.; Punie, K.; Waumans, L.; Laenen, A.; Wildiers, H.; Verdoodt, F.; Desmedt, C.; Ardui, J.; Smeets, A.; Han, S.N.; Nevelsteen, I.; Neven, P.; Floris, G. Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer. Sci. Rep., 2022, 12(1), 22498.
[http://dx.doi.org/10.1038/s41598-022-27093-y] [PMID: 36577919]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy